Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps
oleh: Diego Bagnasco, MD, PhD, Rikki Frank Canevari, MD, Stefano Del Giacco, MD, Silvia Ferrucci, MD, Paolo Pigatto, MD, Paolo Castelnuovo, MD, Gian Luigi Marseglia, MD, Arzu Didem Yalcin, MD, Girolamo Pelaia, MD, Giorgio Walter Canonica, MD
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2022-12-01 |
Deskripsi
Omalizumab is a biological drug targeting circulating IgE, approved for use in allergic asthma, chronic spontaneous urticaria, and recently for chronic rhinosinusitis with nasal polyps, with good efficacy in all these settings. Some concerns about omalizumab safety have been raised as its use has been recently linked to potential increased cancer risk. Nevertheless, literature evidence does not support this statement, and clinical studies and evidence from real-world registries and surveillance analysis have consistently reported drug safety.